Stemtech Corporation (STEK)
Stemtech Corporation operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Naples, FL, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $216,929. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of -155.3%. Its beta of 2.57 implies it has historically moved more than the broad market.
Stemtech Corporation is a pioneering company specializing in stem cell nutrition. It formulates scientifically-backed products designed to optimize the body's intrinsic stem cell physiology. With a market presence spanning the Americas, Latin America, and Asia, its offerings are engineered to bolster the natural functions of the body's stem cells. These solutions achieve this by stimulating the release of more stem cells, facilitating their efficient circulation through the bloodstream, and guiding their migration into various tissues. This process enables the stem cells to perform their continuous regenerative and repair tasks, crucial for maintaining optimal health and vitality. The company's comprehensive portfolio of dietary supplements includes prominent brands such as RCM System, stemrelease3, Stemflo MigraStem, DermaStem, DermaStem Lift, OraStem, and D-Fuze. Stemtech Corporation's operations are headquartered in Miramar, Florida.
Stemtech Corporation is most often compared with the following Healthcare names: